Scott R. McDonnell

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 746 citations · Full text

Tumor Biology, C-met Kinase, Chemoprevention Strategy +15

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

James G. Christensen, Helen Y. Zou, Maria E. Arango et al. · Molecular Cancer Therapeutics · 2007 · 642 citations

Signal Transducers, Immunology, Cell Death +23

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 267 citations · Full text

Inhibitory Activity, Radiation Oncology, Fusion Kinases +14

The CARMA3-Bcl10-MALT1 Signalosome Promotes Angiotensin II-dependent Vascular Inflammation and Atherogenesis

Linda M. McAllister‐Lucas, Xiaohong Jin, Shufang Gu et al. · Journal of Biological Chemistry · 2010 · 77 citations · Full text

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma

Scott R. McDonnell, Steven R. Hwang, Delphine Rolland et al. · Blood · 2013 · 67 citations · Full text